Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers

Prostate cancer is a leading cause of death. Approximately one in eight men who are diagnosed with prostate cancer will die of it. Since there is a large difference in mortality between low- and high-risk prostate cancers, it is critical to identify individuals who are at high-risk for disease progression and death. Germline genetic differences are increasingly recognized as contributing to risk of lethal prostate cancer. The objective of this paper is to review prostate cancer management options for men with high-risk germline mutations.

We performed a review of the literature to identify articles regarding management of prostate cancer in individuals with high-risk germline genetic mutations.

We identified numerous publications regarding the management of prostate cancer among high-risk germline carriers, but the overall quality of the evidence is low.

We performed a review of the literature and compiled clinical considerations for the management of individuals with high-risk germline mutations when they develop prostate cancer. The quality of the evidence is low, and there is an immediate need for further research and the development of consensus guidelines to guide clinical practice for these individuals.